Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities
November 08, 2018 17:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update...
Innovation Pharmaceuticals Expands Brilacidin Patent Portfolio
November 01, 2018 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent...
Innovation Pharmaceuticals Granted End-of-Phase 2 Meeting
October 24, 2018 11:10 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug...
Innovation Pharmaceuticals Provides Update on Kevetrin Program; Bridging Toxicology Efforts Aimed at Developing an Oral p53 Anti-Cancer Drug Candidate
October 22, 2018 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on...
Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference
October 12, 2018 12:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on...
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
October 09, 2018 07:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new...
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments
September 24, 2018 06:59 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a comparative...
Innovation Pharmaceuticals Provides Corporate Update Highlighting Upcoming Milestones and Events
September 20, 2018 09:15 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update on...
Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
September 05, 2018 09:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been...
Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form
July 17, 2018 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a...